Inhibitors of LTβR-NFκB signaling pathways for treating inflammation and cancer
AssigneeUniversity of Maryland, Baltimore
InventorsJonathan Bromberg, Wenji Piao, Yanbao Xiong
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for selective inhibition of the classical or non-classical LTβR-NFκB signaling pathway. In some embodiments, the compositions and methods of the present invention are useful for treating or preventing tissue graft rejection, inflammation, contact hypersensitivity, and cancer by decreasing cell motility.
Claims3
A composition for inhibiting cell motility of a cell selected from the group consisting of a T regulatory cell, a dendritic cell and a cancer cell, comprising an inhibitor of the non-classical LTβR-NFκB signaling pathway, wherein the inhibitor comprises a polypeptide comprising the amino acid sequence of SEQ ID NO:4.
Dependencies are inferred from the claim text.